{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-046525","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.393767+00:00","generated_at":"2026-06-19T03:02:59.635840+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Novartis terminates collaboration with Pliant; discontinues NASH program PLN-1474","bullets":["Novartis notified Pliant on Feb 17, 2023 of termination of Collaboration and License Agreement, effective April 18, 2023.","Novartis is divesting clinical NASH assets and discontinuing development of PLN-1474 (integrin αvβ1 inhibitor for liver fibrosis).","Pliant had received $50M upfront and $29M in contingent payments; up to $416M in future milestones and royalties now terminated.","All rights and licenses, including PLN-1474 and validated research target compounds, revert to Pliant.","Research term for up to three additional integrin targets concludes Q1 2023; one target validated with multiple development candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-046525","json":"https://secwatch.observer/filing/0001193125-23-046525.json","markdown":"https://secwatch.observer/filing/0001193125-23-046525.md","text":"https://secwatch.observer/filing/0001193125-23-046525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000119312523046525/0001193125-23-046525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000119312523046525/d463670d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:02:59.635840+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}